Regulatory Framework for Nanomedicines

  • Costas Demetzos


The nanotechnological products that are released in market are carefully evaluated in the United States by the National Agency for Food and Drugs that is called the Food and Drug Administration (FDA), while in Europe by the European Medicines Agency (EMA). These organizations act according to proposals and recommendations of scientific committees that suggest changes and modifications of the regulatory framework according to scientific, technological, and social facts keeping into consideration as the main concern, the public health. These organizations develop the regulations for law applications related to medicines and medicinal products. The “copies” of nanotechnological medicines that are candidates to release in market are called as nanosimilars. They are off-patent nanotechnological products, and their similarity is considered as an emerging issue to be discussed within the scientific community and moreover in the regulatory bodies which are responsible for their approval. An important issue from the regulatory point of view is innovative excipients that include the self-assembled nanostructures such as liposome, micelles, dendrimers, etc. incorporating bioactive molecules.


Regulatory framework Nanotechnological products Food and Drug Administration (FDA) European Medicines Agency (EMA) Nanosimilars 


  1. 1.
    Ahmed I, Kaspar B, Sharma U (2012) Biosimilars: impact of biological products life cycle and European experience on the regulatory trajectory in the United States. Clin Ther 34:400–419CrossRefPubMedGoogle Scholar
  2. 2.
    Bawa R, Johnson S (2007) The ethical dimensions of nanomedicine. Med Clin N Am 91(5):881–887CrossRefPubMedGoogle Scholar
  3. 3.
    Demetzos C, Pippa N (2015) Fractal geometry as a new approach for proving nanosimilarity: a reflection paper. Int J Pharm 483:1–5CrossRefPubMedGoogle Scholar
  4. 4.
    Demetzos C, Pippa N, Tountas Y (2013) Advanced therapies: new guidelines and the approval process. Pharmakeftiki 25(II):49–54Google Scholar
  5. 5.
    Directive 201/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use Off J Eur Union 28 11 2001Google Scholar
  6. 6.
    Gaspar R (2007) Regulatory issues surrounding nanomedicines: setting the scene for the next generation of nanopharmaceuticals. Nanomedicine 2:143–147CrossRefPubMedGoogle Scholar
  7. 7.
    Holloway C, Mueller-Berghaus J, Lima BS et al (2012) Scientific consideration for complex drugs in light of established and emerging regulatory guidance. Ann N Y Acad Sci 1276:26–36CrossRefPubMedGoogle Scholar
  8. 8.
    Narang AS, Chang RK, Hussain MA (2013) Pharmaceutical development and regulatory considerations for nanoparticles and nanoparticulate drug delivery systems. J Pharm Sci 102:3867–3882CrossRefPubMedGoogle Scholar
  9. 9.
    Regulation (EC) No 1394/2007 of the European Parliament and the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004. Off J Eur Union 10 12 2007Google Scholar
  10. 10.
    Resnik DB, Tinkle SS (2007) Ethics in nanomedicine. Nanomedicine 2:345–350CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Schellekens H, Klinger E, Muhlebach S et al (2011) The therapeutic equivalence of complex drugs. Regul Toxicol Pharmacol 59:176–183CrossRefPubMedGoogle Scholar
  12. 12.
    Stephan MT, Moon JJ, Um SH et al (2010) Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat Med 16:1035–1041CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Tsiftsoglou AS, Ruiz S, Scheneider CK (2013) Development and regulation of biosimilars: current status and future challenges. BioDrugs 27(3):203–211CrossRefPubMedGoogle Scholar
  14. 14.
    Vamvakas S, Martinaldo J, Pita R et al (2011) On the edge of new technologies (advanced therapies nanomedicines). Drug Discov Today Technol 8:e21–e28CrossRefGoogle Scholar
  15. 15.
    van Calster G (2006) Regulating nanotechnology in the European Union. Nanotechnol Law Bus 3:359–372Google Scholar
  16. 16.
    Wagner V, Dullaart A, Bock AK, Zweck A (2006) The emerging nanomedicine landscape. Nat Biotechnol 24:1211–1217CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Singapore 2016

Authors and Affiliations

  • Costas Demetzos
    • 1
  1. 1.Faculty of PharmacyNational & Kapodistrian University of AthensZografouGreece

Personalised recommendations